Background Topical corticosteroids may be needed for treating skin conditions in pregnancy. Nevertheless, only lim-
Introduction
Topical corticosteroids are frequently prescribed for treating various dermatoses including eczema, 1 psoriasis, 2 lichen sclerosus 3 and bullous pemphigoid. 4 Women with these dermatoses may need topical corticosteroid treatment during pregnancy. Pregnant women with specific dermatoses of pregnancy, for example atopic eruption of pregnancy, need topical corticosteroid treatment as well. 5 Nevertheless, the effects of topical corticosteroids on the fetus are largely unclear. Drug references, for example the British National Formulary, do not provide explicit instructions on prescribing topical corticosteroids in pregnancy. 6 A typical labelling for use of topical corticosteroids in pregnancy is 'should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus'.
corticosteroids in pregnancy may result in physicians' hesitancy and non-or underprescribing. Pregnant women's overconcern of fetal risk may lead to underuse of topical corticosteroids and decreased therapeutic effects. A previous survey of 250 directors of departments of dermatology across Europe found 30% were concerned about prescribing topical corticosteroids to pregnant women and 91% restrained their prescribing. 8 For making an informed clinical decision on the use of topical corticosteroids in pregnancy, an evidence-based guideline is warranted. We organized a guideline subcommittee of the European Dermatology Forum and have developed an evidence-based (S3) guideline on the use of topical corticosteroids in pregnancy in 2011. 9 Herein we present an updated guideline in which we added and appraised new evidence.
Disclaimer
This guideline was developed by the European Dermatology Forum (available at http://www.euroderm.org/edf/index.php/ edf-guidelines/category/5-guidelines-miscellaneous). The recommendations reflect the best data available at the time when this guideline was prepared. Caution should be exercised in interpreting the data; the results of future studies may require alteration of the conclusions or recommendations in this report. It may be necessary or even desirable to depart from these recommendations in special circumstances. Just as adherence to guidelines may not constitute defence against a claim of negligence, so deviation from them should not be necessarily deemed negligent.
Levels of evidence and grades of recommendation
Much has been written in recent years on the need for clinical guidelines and the criteria they should meet for development and application, as well as evidence and recommendations to be used in their support. We used the levels of evidence defined by the Oxford Centre for Evidence-Based Medicine (Table 1) 10 and GRADE's approach to rating quality of evidence (Table 2) .
11
The quality of evidence from randomized trials is initially rated as high and observational studies as low. Further evaluation may upgrade the quality of evidence for large-magnitude effect, dose response and confounders likely to minimize the effect, and may downgrade due to study limitations, imprecision, inconsistency of results, indirectness of evidence and publication bias.

Evidence for harm from animal studies
Animal experiments showed corticosteroids have fetotoxic effects and are teratogenic. Administration of systemic corticosteroids resulted in cleft palate in rabbits, mice, rats and hamsters. [12] [13] [14] [15] The occurrence of genital organ anomalies in mice correlated with the amounts of corticosteroids applied to the eyes. 16 Administration of dexamethasone in juvenile rhesus monkeys resulted in permanent loss of hippocampal neurons, and elevated plasma cortisol levels at the circadian baseline and poststress concentrations. 17 The birthweight of fetal lambs reduced after prenatal administration of betamethasone in a dose-response relationship. 18 One animal experiment illustrated that after application on the mothers' skin, appreciable levels of betamethasone 17,21-dipropionate were detected in the fetal blood of mice and rabbits. 19 Animal studies have found topical corticosteroids are also teratogenic. Diflorasone diacetate cream caused cleft palate after application to pregnant rats' skin at a dose of 0.001 mg/kg/day, which was just one-third of the equivalent human topical dose. The treated rats had a higher rate of fetal death than untreated controls when the dose was increased to 0.5 mg/kg/day. 20 After topical application of diflorasone diacetate 0.016 mg/kg/day to pregnant rabbits, depressed fetal growth, external anomalies (31.9%), cleft palate (22.2%) and visceral defects (45.5%) were found. 21 To sum up, animal experiments demonstrated that topical application of topical corticosteroids to pregnant rodents resulted in teratogenic effects, fetal growth restriction and Systematic review of randomized trials or n-of-1 trial
Level 2
Randomized trial or (exceptionally) observational study with dramatic effect
Level 3
Non-randomized controlled cohort/follow-up study (postmarketing surveillance) provided there are sufficient numbers to rule out a common harm. (For long-term harms, the duration of follow-up must be sufficient.)**
Level 4
Case series, case-control or historically controlled studies**
Level 5
Mechanism-based reasoning *Level may be graded down on the basis of study quality, imprecision and indirectness (study PICO does not match questions PICO), because of inconsistency between studies, or because the absolute effect size is very small; level may be graded up if there is a large or very large effect size. **As always, a systematic review is generally better than an individual study. increased fetal death, but these experiments cannot be extrapolated to humans as the stratum corneum of the animals is much thinner and the percutaneous absorption is much higher than in humans.
Pharmacology and pharmacokinetics in the mother
The systemic effects of topical corticosteroids rely on the degree of percutaneous absorption and the pharmacokinetic pathways for systemically absorbed corticosteroids. Corticosteroids are bound to plasma proteins, metabolized mainly in the liver, excreted in the kidney and cross the placenta in pregnant women.
Skin absorption and bioavailability of topical corticosteroids in pregnancy The systemic effects of topical corticosteroids largely depend on the extent of percutaneous absorption, which varies from <0.5% to 7% when applied to intact skin, 22, 23 and also on systemic bioavailability (see Fig. 1 ). The degree of percutaneous absorption, and hence the potential for systemic exposure, depends upon the following factors: 24 • the nature of the corticosteroid chemical compound;
• the nature of the vehicle;
• the integrity of the skin barrier;
• the use of occlusion;
• the surface area and regional anatomic variation of the treated skin;
• the frequency and duration of application;
• the metabolism of corticosteroids;
• inflammation and/or other diseases in the skin;
• pregnancy (there may be variation in different trimesters).
Hydrocortisone and other corticosteroids have various systemic bioavailability following topical application due to different lipophilicity, degradability and other pharmacokinetic properties. Hydrocortisone, the least potent corticosteroid, is able to suppress the adrenals following long-term use in children with dermatitis. 25 Clobetasol propionate ointment, the most potent topical corticosteroid, may cause adrenal insufficiency at a very low dose of 2 g per day for 1 week. 22 Adrenal suppression after application of newer topical lipophilic corticosteroids (i.e. mometasone furoate, fluticasone propionate and methylprednisolone aceponate) under extreme conditions has been documented, 26 ,27 but was not found for mometasone furoate under more moderate conditions (10 g/day) 28 or in psoriatic patients (15 g/day). 29 The vehicle may enhance penetration and promote systemic absorption. The use of occlusive dressings, hydration of skin, application over large surface areas, and prolonged use can enhance systemic absorption. Percutaneous penetration is increased over thin skin including the face, intertriginous areas and genital area.
Inflammation and other conditions of the skin may enhance percutaneous absorption of topical corticosteroids. The percutaneous absorption of 1% hydrocortisone cream during flares of eczema increased to 11-31 times that in remission. 30 While only <0.5% of applied methylprednisolone aceponate was absorbed through intact skin, removal of the skin barrier by stripping increased the absorption to 15.4 AE 7.7%. 23 The change in the hydration and blood flow of the skin in pregnancy may alter the systemic bioavailability of topical corticosteroids. 31 Nevertheless, there have been no studies on the systemic bioavailability of topical corticosteroids in pregnant women for ethical concerns. The data from nasal and inhaled corticosteroids may not be directly applicable to the skin. The systemic bioavailability of fluticasone propionate and mometasone furoate through these routes is very low; [32] [33] [34] however, the data could not be directly extrapolated to cutaneous application. The newer lipophilic corticosteroids including fluticasone propionate, mometasone furoate and methylprednisolone aceponate should perhaps be preferred based on fewer local and systemic side-effects, 35 ,36 but direct evidence from pregnant women is lacking. However, these newer corticosteroids do have a better risk-benefit rescue regarding cutaneous side-effects and are maybe preferable due to this benefit. In addition, they also have been marketed now for more than 20 years and used worldwide in a very high number of patients, giving further indirect evidence for safety by the lack of reported side-effects.
Metabolism of corticosteroids Over 90% of absorbed corticosteroids in the plasma reversibly combine with two plasma proteins: corticosteroid-binding globulin (CBG) and albumin. Only unbound corticosteroids can enter cells to exert actions. Most of circulating corticosteroids are bound at normal or low plasma levels. At higher plasma levels of corticosteroids, the binding capacity of proteins is overwhelmed, and a greater proportion of the corticosteroids are in the free form. A specific circumstance of physiological hypercorticism happens in pregnancy. The high circulating oestrogen levels promote the production of CBG, resulting in elevated total plasma cortisone levels. The physiological significance of these changes during pregnancy on exogenous corticosteroids is unclear. Corticosteroids are metabolized in the liver to water-soluble compounds which are excreted by the kidneys.
Placental metabolism
The fetal effects of corticosteroids reply on their extent of transplacental passage (Table 3 ). The key metabolizing enzyme of corticosteroids in the placenta is 11b-hydroxysteroid dehydrogenase (11bHSD) that transforms biologically active cortisol (hydrocortisone) into biologically inactive cortisone. Therefore, 11bHSD is the gatekeeper in limiting the quantities of maternal cortisol that pass through the placenta to enter the fetus and in protecting the fetus from unwanted harm. 37 Hydrocortisone is assumed safe for use in pregnancy because of the weak potency and high metabolism in the placenta. However, one study using the fetal-placental unit before abortion found 15% of 3 H-cortisol passed through the placenta without being metabolized, 38 and another study illustrated a linear relationship between maternal and fetal serum cortisol levels. 39, 40 Only 10-12% of prednisolone passed through the placenta. 41 In the meanwhile, dexamethasone, methylprednisolone and betamethasone are less metabolized by the placenta, and 67%, 45% and 30% reached the fetus, respectively. 42 Fluticasone propionate and budesonide are unmetabolized, 43 and thus, high amounts of them pass through the placenta. To the best of our knowledge, there is a lack of relevant studies on other corticosteroids. However, the newer corticosteroids such as mometasone, which shows a firstpass effect in the liver, are most likely not to pass the placenta in significant levels, if -like in other corticosteroids -a linear relationship between the maternal and the fetal serum may be assumed. In addition, mometasone is strongly bound to plasma proteins and the free fraction is approximately 10-20 times lower compared to other corticosteroids 44 which should also lead to lower transition into the placenta.
Evidence from human studies
The data available as to possible fetal harm from use of topical corticosteroids in pregnancy were limited. The current best evidence is from a recently updated Cochrane review published in 2015. 45, 46 The review authors systematically searched 10 databases including the Cochrane Skin Group Specialised Register, the Cochrane Pregnancy and Childbirth Group Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, LILACS and five trial registers. They identified 14 relevant studies, including five cohort and nine casecontrol studies which covered a total of 1 601 515 subjects (Table 4) . [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] A pregnant woman co-author has been involved in preparing this review. The available data were mostly related to orofacial cleft (level of evidence: 3). The majority of the included studies found no significant associations between maternal use of topical corticosteroids and adverse pregnancy outcomes including mode of delivery, birth defect, preterm delivery and fetal death, although these studies all had certain limitations. [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] 58 A significant association between topical corticosteroids and orofacial cleft was found in one small casecontrol study, 57 while none of other included studies showed a similar effect. Two cohort studies showed a significant association between maternal use of potent/very potent topical corticosteroids and low birthweight. 55, 59 One further study identified an increased risk of low birthweight when the dispensed amounts of potent/very potent topical corticosteroids were more than 300 g during pregnancy (Table 5) . 56 
Conclusions
The available data on the safety of topical corticosteroids in pregnancy suggest a lack of associations of their use by the mother with birth defect, preterm birth and fetal death. Limited evidence does suggest a significant association of maternal use of potent/very potent topical corticosteroids, especially in large amounts, with low birthweight. 55, 56, 59 However, the finding was from only two research groups. Further studies are warranted for reproducing this finding.
Recommendations
• Mild/moderate topical corticosteroids should be used in preference to more potent corticosteroids in pregnancy (low-quality evidence).
• Potent/very potent topical corticosteroids should be used as second-line therapy for as short a time as possible, and appropriate obstetric care should be provided as they increase the risk of low birthweight (low-quality evidence).
• The association between maternal exposure to potent/very potent topical corticosteroids and fetal growth restriction needs to be considered when applying them during pregnancy. However, systemic corticosteroids have a greater In summary, it is difficult to predict the effects of topically applied corticosteroid used by the mother on the unborn child, as there are so many independent factors. Clinical trials are unethical and therefore have never been conducted. Guideline on topical steroids in pregnancy bioavailability than that of topical corticosteroids, and thus have a greater potential for fetotoxicity than topical corticosteroids (systemic corticosteroids are associated with a reduction in fetal birthweight and an increase in preterm delivery), 60, 61 and should not be used in preference (lowquality evidence).
• On theoretical grounds the danger of adverse events is increased when areas with high absorption (e.g. genitals, eyelids, flexures) are treated (very low-quality evidence).
• In eczema where the skin barrier is impaired due to the genetic loss-of-function mutations in the filaggrin gene, 62 the risk of adverse events may be increased.
• There are no data available to determine whether newer lipophilic topical corticosteroids (mometasone furoate, fluticasone propionate and methylprednisolone aceponate) with a good therapeutic index ( Fig. 1 ) are associated with a less risk of low birthweight. On theoretical grounds, a favourable side-effect profile for the use in pregnancy is suggested; furthermore, they have the practical advantage of once-daily application compared to older preparations (very low-quality evidence).
Advice to women about using topical corticosteroids in pregnancy
• Women can be reassured that there is no significantly increased risk of birth defect, preterm delivery and fetal death while using topical corticosteroids for medical indications in pregnancy. There is also no increased risk of low birthweight when using mild/moderate topical corticosteroids in pregnancy. Guideline on topical steroids in pregnancy
• Women should be informed that there is a small risk for low birthweight when using potent/very potent topical corticosteroids in pregnancy, but this risk is less than that of systemic corticosteroids, for an additional risk for miscarriage and preterm delivery has been found in pregnant women using systemic corticosteroids.
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• Depending on the severity of their skin conditions, pregnant women should use topical corticosteroids of the least potency required and limit the use amounts. Pregnant women should be cautious on sites of high percutaneous absorption, for example the skin folds, armpits and vulva. Pregnant women with eczema shall apply as least amounts of topical corticosteroids as possible because the skin barrier is impaired. Details of the search strategies for CENTRAL, MEDLINE and EMBASE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the 'Specialized Register' section within the editorial information about the Cochrane Pregnancy and Childbirth Group.
Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Coordinator searches the register for each review using the topic list rather than keywords.
Appendix 3: CENTRAL (Cochrane Library) strategy
